Information Provided By:
Fly News Breaks for February 10, 2017
SGEN
Feb 10, 2017 | 07:51 EDT
BofA/Merrill analyst Tazeen Ahmad downgraded Seattle Genetics to Underperform and lowered its price target to $56 from $58 to reflect tempered expectations for E-1 and E-2.
News For SGEN From the Last 2 Days
There are no results for your query SGEN